Bucindolol has been investigated in Heart Failure.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Bucindolol may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Bucindolol may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Bucindolol. |
| Atomoxetine | The risk or severity of hypertension can be increased when Atomoxetine is combined with Bucindolol. |
| Linezolid | The risk or severity of hypertension can be increased when Linezolid is combined with Bucindolol. |
| Amiodarone | The therapeutic efficacy of Bucindolol can be increased when used in combination with Amiodarone. |
| Bupivacaine | The serum concentration of Bupivacaine can be increased when it is combined with Bucindolol. |
| Dipyridamole | Dipyridamole may increase the bradycardic activities of Bucindolol. |
| Disopyramide | Disopyramide may increase the bradycardic activities of Bucindolol. |
| Dronedarone | Dronedarone may increase the bradycardic activities of Bucindolol. |
| Fingolimod | Bucindolol may increase the bradycardic activities of Fingolimod. |
| Floctafenine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Floctafenine. |
| Mepivacaine | The serum concentration of Mepivacaine can be increased when it is combined with Bucindolol. |
| Methacholine | Bucindolol may increase the bronchoconstrictory activities of Methacholine. |
| Midodrine | The therapeutic efficacy of Midodrine can be decreased when used in combination with Bucindolol. |
| Nifedipine | The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bucindolol. |
| Propafenone | The risk or severity of adverse effects can be increased when Propafenone is combined with Bucindolol. |
| Regorafenib | Regorafenib may increase the bradycardic activities of Bucindolol. |
| Reserpine | Reserpine may increase the hypotensive activities of Bucindolol. |
| Deserpidine | Deserpidine may increase the hypotensive activities of Bucindolol. |
| Guanethidine | Guanethidine may increase the hypotensive activities of Bucindolol. |
| Rivastigmine | Bucindolol may increase the bradycardic activities of Rivastigmine. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Bucindolol. |
| Lurasidone | Bucindolol may increase the hypotensive activities of Lurasidone. |
| Mirabegron | The serum concentration of Bucindolol can be increased when it is combined with Mirabegron. |
| Tedizolid phosphate | Tedizolid phosphate may increase the hypertensive activities of Bucindolol. |
| Insulin argine | Bucindolol may increase the hypoglycemic activities of Insulin argine. |
| Caffeine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Caffeine. |
| Dyphylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Dyphylline. |
| Pentoxifylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Pentoxifylline. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Mercaptopurine. |
| Aminophylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Aminophylline. |
| Oxtriphylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Oxtriphylline. |
| Theobromine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Theobromine. |
| Fenethylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Fenethylline. |
| 8-azaguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 8-azaguanine. |
| 7,9-Dimethylguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 7,9-Dimethylguanine. |
| Xanthine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Xanthine. |
| 7-Deazaguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 7-Deazaguanine. |
| Guanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Guanine. |
| 9-Methylguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 9-Methylguanine. |
| Peldesine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Peldesine. |
| Hypoxanthine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Hypoxanthine. |
| 9-Deazaguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 9-Deazaguanine. |
| Propentofylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Propentofylline. |
| Valomaciclovir | The risk or severity of adverse effects can be increased when Bucindolol is combined with Valomaciclovir. |
| 3-isobutyl-1-methyl-7H-xanthine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 3-isobutyl-1-methyl-7H-xanthine. |
| Uric acid | The risk or severity of adverse effects can be increased when Bucindolol is combined with Uric acid. |
| 6-O-benzylguanine | The risk or severity of adverse effects can be increased when Bucindolol is combined with 6-O-benzylguanine. |
| Lisofylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Lisofylline. |
| Lobucavir | The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobucavir. |
| Cafedrine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Cafedrine. |
| Bamifylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Bamifylline. |
| Proxyphylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Proxyphylline. |
| Acefylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Acefylline. |
| Etamiphylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Etamiphylline. |
| Pentifylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Pentifylline. |
| Bufylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Bufylline. |
| Bromotheophylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Bromotheophylline. |
| Furafylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Furafylline. |
| 8-chlorotheophylline | The risk or severity of adverse effects can be increased when Bucindolol is combined with 8-chlorotheophylline. |
| PCS-499 | The risk or severity of adverse effects can be increased when Bucindolol is combined with PCS-499. |
| Iobenguane | Bucindolol can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nicotine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Nicotine. |
| Cevimeline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Cevimeline. |
| Carbamoylcholine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Carbamoylcholine. |
| Bethanechol | The risk or severity of adverse effects can be increased when Bucindolol is combined with Bethanechol. |
| Pilocarpine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Pilocarpine. |
| Varenicline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Varenicline. |
| Acetylcholine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Acetylcholine. |
| Arecoline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Arecoline. |
| Lobeline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline. |
| NGX267 | The risk or severity of adverse effects can be increased when Bucindolol is combined with NGX267. |
| GTS-21 | The risk or severity of adverse effects can be increased when Bucindolol is combined with GTS-21. |
| Epibatidine | The risk or severity of adverse effects can be increased when Bucindolol is combined with Epibatidine. |
| Xanomeline | The risk or severity of adverse effects can be increased when Bucindolol is combined with Xanomeline. |
| Thiethylperazine | The serum concentration of Bucindolol can be increased when it is combined with Thiethylperazine. |
| Prochlorperazine | The serum concentration of Bucindolol can be increased when it is combined with Prochlorperazine. |
| Triflupromazine | The serum concentration of Bucindolol can be increased when it is combined with Triflupromazine. |
| Fluphenazine | The serum concentration of Bucindolol can be increased when it is combined with Fluphenazine. |
| Moricizine | The serum concentration of Bucindolol can be increased when it is combined with Moricizine. |
| Perphenazine | The serum concentration of Bucindolol can be increased when it is combined with Perphenazine. |
| Mesoridazine | The serum concentration of Bucindolol can be increased when it is combined with Mesoridazine. |
| Acetophenazine | The serum concentration of Bucindolol can be increased when it is combined with Acetophenazine. |
| Promethazine | The serum concentration of Bucindolol can be increased when it is combined with Promethazine. |
| Alimemazine | The serum concentration of Bucindolol can be increased when it is combined with Alimemazine. |
| Aceprometazine | The serum concentration of Bucindolol can be increased when it is combined with Aceprometazine. |
| Pipotiazine | The serum concentration of Bucindolol can be increased when it is combined with Pipotiazine. |
| BL-1020 | The serum concentration of Bucindolol can be increased when it is combined with BL-1020. |
| Cyamemazine | The serum concentration of Bucindolol can be increased when it is combined with Cyamemazine. |
| Methylene blue | The serum concentration of Bucindolol can be increased when it is combined with Methylene blue. |
| Propiopromazine | The serum concentration of Bucindolol can be increased when it is combined with Propiopromazine. |
| Perazine | The serum concentration of Bucindolol can be increased when it is combined with Perazine. |
| Butaperazine | The serum concentration of Bucindolol can be increased when it is combined with Butaperazine. |
| Chlorproethazine | The serum concentration of Bucindolol can be increased when it is combined with Chlorproethazine. |
| Thiazinam | The serum concentration of Bucindolol can be increased when it is combined with Thiazinam. |
| Dixyrazine | The serum concentration of Bucindolol can be increased when it is combined with Dixyrazine. |
| Perphenazine enanthate | The serum concentration of Bucindolol can be increased when it is combined with Perphenazine enanthate. |
| Digoxin | Bucindolol may increase the bradycardic activities of Digoxin. |
| Acetyldigitoxin | Bucindolol may increase the bradycardic activities of Acetyldigitoxin. |